TKTuba Kuruoğlu

Tuba Kuruoğlu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Tuba Kuruoğlu has a total of 96 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative evaluation of a novel saliva collection strip and nasopharyngeal swab for SARS-CoV-2 validated by in-house RT-qPCR

    by Ahmet C Orbay, Tuba Kuruoglu, Derya Bayirli Turan, Emine H Erdeniz, Demet Gur Vural, Deniz Kirac

    Introduction: The most commonly used sample collection method for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is nasopharyngeal swab; however, sample collection, especially from pediatric patients, is difficult. Therefore, the aim of this study was to design a saliva collection strip and to compare the effectiveness of this strip with the nasopharyngeal swab. Additionally, the performance of different isolation procedures before real time quantitative polymerase chain reaction (RT-qPCR) were investigated and an in-house RT-qPCR assay was developed. Methodology: A total of 200 samples was collected from patients and 92 samples were confirmed as SARS-CoV-2 positive. In the first technique, nucleic acid from the samples were isolated using different isolation methods, and then analyzed by RT-qPCR. In the second technique, the samples were analyzed directly by RT-qPCR without any isolation process. Additionally, in-house RT-qPCR assay was performed and the results were compared with conventional RT-qPCR. Results: The cycle threshold (Ct) values were compared between the techniques, and very similar results were obtained with all of the methods. This reveals that both sample collection methods, both isolation methods, and both RT-qPCR assays had comparable accuracy. Conclusions: In this study, in-house optimization, validation, and integration of the SARS-CoV-2 assay with both isolation-based and extraction (direct lysis) workflows were compared. In addition, its compatibility with the newly designed saliva strip collection system was analyzed. Very similar results were obtained from all of the methods. Therefore, the sample collection strip and in-house assay can be useful tools for detecting SARS-CoV-2.

  • Ruksolitinib Kullanan Miyelofibrozis Hastasında Nekrotizan Fasiiti Taklit Eden Kutanöz Cryptococcus neoformans Enfeksiyonu: Bir Olgu Sunumu

    by Tuba Kuruoğlu, Tuba Sena Karaçeşme, Sümeyye Ekmekçi̇ Kurt, Elifsu Beni̇ç, Emel Duyar, Murat Erdoğan, Esra Yartaşi, Asuman Bi̇rİnCi̇, Deniz Bayçelebi

    Cryptococcus neoformans is an encapsulated opportunistic yeast widely distributed in the environment and classified as critical-priority fungal pathogen by the World Health Organisation due to its high mortality and limited access to timely diagnosis and effective treatment. Infection is typically acquired via inhalation, with the primary pulmonary focus often remaining asymptomatic. Particularly in individuals with impaired cell-mediated immunity, it may disseminate hematogenously to central nervous system (CNS), skin and other organs. Cutaneous cryptococcosis is a rare clinical manifestation and in most cases, represents secondary involvement of disseminated disease. Its clinical presentation is highly variable and may mimic cellulitis, abscesses, ulcers or necrotizing soft-tissue infections, posing significant diagnostic challenges. Ruxolitinib is a Janus-kinase inhibitor used to treat myelofibrosis and polycythemia vera. By suppressing interferon-γ and interleukin-12-mediated immune responses, it impairs macrophage activation, reduces T-helper-1 cell responses, suppresses natural-killer cell function, and regulates hematopoietic activity. However, these immunomodulatory effects predispose patients to invasive opportunistic infections, particularly fungal infections. In the literature, cryptococcal infections associated with ruxolitinib have been reported in a limited number of case reports, most commonly involving the pulmonary and/or central nervous system. Cutaneous involvement is exceedingly rare, and to date, no cases from Türkiye have been reported. In this case report, a 67-year-old woman with myelofibrosis who had been receiving ruxolitinib therapy for three-years and developed cutaneous cryptococcosis infection mimicking necrotizing fasciitis, accompanied by asymptomatic pulmonary involvement was presented. Despite broad-spectrum antibacterials, a small papule on the medial thigh rapidly progressed over 25 days, with severe disproportionate pain raising suspicion of necrotizing fasciitis. On admission, physical examination revealed an 8×8 cm ulcerative tissue defect on the left thigh, with surrounding erythema, ecchymosis, desquamation and hemopurulent discharge. Magnetic resonance imaging demonstrated findings suggestive of necrotising soft-tissue infection, prompting urgent surgical intervention. Intraoperatively, diffuse inflammation and patchy necrotic areas were observed and surgical debridement followed by vacuum-assisted wound closure was performed. Microbiological cultures of deep-tissue specimens yielded C.neoformans and the pathogen was confirmed by matrix-assisted laser desorption/ ionisation-time-of-flight-mass spectrometry (MALDI-TOF-MS). Antifungal susceptibility testing showed minimum inhibitory concentrations of 0.5 µg/mL for amphotericin B and 4 µg/mL for fluconazole. Histopathological examination demonstrated yeast cells within a background of suppurative inflammation and focal necrosis. Although the patient had no respiratory symptoms, chest computed tomography revealed a cavitary pulmonary nodule consistent with fungal infection. Bronchoalveolar lavage cultures showed no microbial growth. Evaluation for central nervous system involvement resulted negative for India-ink staining and cerebrospinal fluid multiplex polymerase chain reaction (PCR) test. These findings were considered consistent with systemic cryptococcosis involving the skin and lungs. Antibacterials were discontinued and intravenous liposomal amphotericin-B plus fluconazole was initiated. After central netvous system involvement was excluded, sequential therapy with fluconazole was planned. Ruxolitinib dose was adjusted by haematology. Significant clinical improvement was observed in the early phase of treatment and pain however, the patient died due to acute pulmonary embolism. This case highlights a rare cutaneous presentation of ruxolitinib-associated cryptococcosis and emphasizes the importance of clinical awareness for opportunistic fungal infections in immunosuppressed patients.


  • Orta-Karadeniz Bölgesinde Kızamık Seroprevalansının İncelenmesi: Kesitsel Çalışma

    by Tuba Sena Karaçeşme, Fatih Temoçi̇n, Tuba Kuruoğlu, Aynur Ati̇lLa, Emine Hafize Erdeni̇z, Canberk Çinar, Esra Tanyel

  • Bir Üniversite Hastanesi Yoğun Bakım Ünitesinde Candida auris Vakası

    by Asuman Birinci, Canberk Çınar, Tuba Kuruoğlu, Fatih Temoçin, Yeliz Tanrıverdi Çaycı

    Candida auris tanımlanmasından sonra hızla önemli bir enfeksiyon etkeni haline gelmiştir. Dirençli bir mantar olması, kolonizasyon özelliğinin olması, tanımlanmasının zor olması bu mantarı önemli yapan özellikleridir. Bu çalışmada Ondokuz Mayıs Üniversitesi Tıp Fakültesinde saptanan ilk C. auris enfeksiyonu olgusunun bildirilmesi ve önemli bir tehdit olan C. auris enfeksiyonlarının önemine dikkat çekilmesi amaçlanmıştır. Olgu 52 yaşında erkek hasta, bilinen ek hastalığı yok. Metil alkol kullanımına bağlı bilinç bulanıklığı ile acil servise getirildi. Yatışının 40. gününde idrar kültüründe T. asaii ile C. auris üremesi oldu. Konvansiyonel yöntemlerden sonra üreyen koloniler matriks destekli lazer dezorpsiyon iyonizasyon uçuş zamanı kütle spektroskopisi yöntemi kullanılarak tanımlandı. C. auris bilindiği üzere azollere sık olarak direnç geliştirebilmekte ve bazen tüm antifungallere dirençli de olabilmekteydi. Bizim çalışmamızda da literatür ile uyumlu olarak azoller için daha yüksek minimum inhibitör konsantrasyonları göstermiştir. Hastanelerde C.auris’in erken tanısı, doğru tedavisi ve yayılımının önlenmesi açısından etkene yönelik enfeksiyon kontrol önlemlerinin alınması uygun olacaktır.

  • Open Access

    Ceftazidime-Avibactam: A Retrospective Analysis of Multicenter Real-World Data and Factors Affecting Mortality

    by Nazlım Aktuğ-Demir, Fatih Temoçin, Onur Ural, Ezgi Gülten, Ayşe Seza İnal, Çiğdem Kader, Yasemin Ersoy, Ali Asan, Pınar Aysert-Yıldız, Şua Sümer, et al.

    Objective: Multidrug-resistant Gram-negative bacteria cause difficult-to-treat infections associated with high mortality. Carbapenems are widely used; however, their overuse has led to the emergence of carbapenem-resistant bacteria. This study aimed to evaluate the indications, clinical and microbiological efficacy, and side effects of ceftazidime-avibactam (CAZ-AVI) and to identify factors influencing mortality, based on data from a large multicenter patient cohort in Türkiye. Materials and Methods: Patients with carbapenem-resistant but CAZ-AVI-susceptible Gram-negative bacterial infections who received CAZ-AVI treatment were retrospectively reviewed. Results: A total of 1245 patients were included. The most common indication for CAZ-AVI use was hospital-acquired pneumonia (47.8%). Klebsiella pneumoniae was the predominant pathogen (81.3%). CAZ-AVI was used as a monotherapy in 80% of cases. Clinical side effects were observed in 8 (0.64%) patients, while laboratory abnormalities occurred in 73 (5.86%). The 7-day, 14-day, and 28-day all-cause mortality rates were 13.8%, 28.9%, and 45.2%, respectively. Microbiological eradication was achieved in 82.3% of patients. Higher Sequential Organ Failure Assessment (SOFA) and Acute Physiology and Chronic Health Evaluation II (APACHE II) scores at admission, requirement for continuous renal replacement therapy, mechanical ventilation, and elevated C-reactive protein levels were identified as independent risk factors for mortality. Conclusion: This large multicenter real-world analysis demonstrates that CAZ-AVI is an effective treatment option for severe infections with high mortality, such as those caused by carbapenem-resistant Enterobacterales and Pseudomonas aeruginosa.


  • Open Access

    Detrimental Effects of Sterilization Types on Single-Use Coronary Angioplasty Catheters for Reuse: An Electron Microscopic Study

    by Tuba Kuruoğlu, Mehmet Emin Önger, Gamze Altun, Aynur Atilla, Şaban Esen

    Reprocessing a disposable medical device in which sterility deteriorates without contact with the blood and body fluids is called “reprocessing.” If it is ready for use by being processed again for the same or another patient, it is named reuse. The increasing number of blood-borne diseases led to the broader use of disposable instruments. Cardiac catheters, (...)


  • Investigation of Anti-SARS-CoV-2-specific IgG Levels in Breast Milk after Vaccination or COVID-19 Infection

    by Fatih Temocin, Yeliz Tanrıverdi Çaycı, Canan Seren, Tuba Kuruoglu, Aynur Atilla, Asuman Birinci, Esra Tanyel

    Objective Newborns are vulnerable to all types of infections due to their developing immune system. To compensate for their immune immaturity, newborns rely on the passive transfer of antibodies through the placenta and own mother's breast milk (BM). In the present study, we investigated whether vaccination against SARS-CoV-2 leads to the presence of antibodies in BM. Furthermore, we compared the levels of SARS-CoV-2-specific anti-spike (anti-S) IgG antibodies in the BM of mothers who were vaccinated against Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or had coronavirus disease 2019 (COVID-19) infection naturally or were vaccinated after natural infection. Study Design This was a prospective cohort study conducted in the Ondokuz Mayis University Faculty of Medicine. Forty-six mothers who had at least two doses of the BNT162b2 messenger RNA-based vaccine and/or had a history of symptomatic COVID-19 infection were included in the study. BM samples were analyzed by the Abbott Architect SARS-CoV-2 IgG II Quant kit following the manufacturer's instructions. Results Forty-six mothers with an average age of 29.7 ± 5.7 years participated the study: 18 (39.1%) had COVID-19 infection + BTN162b2 vaccine, 17 (37.0%) had BTN162b2 vaccine, and 11 (23.9%) had natural infection. The highest SARS-CoV-2-specific anti-S IgG antibody titers in BM were found in mothers who were vaccinated following the infection (anti-SARS-CoV-2 IgG: 32.48 ± 57.1 arbitrary units AU/mL). However, no significant difference in anti-SARS-CoV-2 antibody levels was observed between the three groups (p = 0.641). No antibody was detected in 15.2% of BM samples. Conclusion Both vaccination and natural COVID-19 infection during pregnancy leads to the passive transfer of specific anti-SARS-CoV-2 IgG antibodies to BM. These results are important to overcome vaccine hesitancy and increase vaccination levels in expectant mothers. Key Points


  • Open Access

    Evaluation of risk factors for the development of bacteremia and complications in patients with brucellosis: Is it possible to predict the clinical course?

    by Tuba Kuruoglu, Levent Sensoy, Aynur Atilla, Fatih Temocin, Demet Gur, Esra Tanyel

    Introduction: Brucellosis is often confused with other diseases or accompanies the conditions it imitates. It causes treatment delays, failure, relapse, and complications. This study aimed to investigate bacteremia and complication predictors in Brucellosis patients. Early detection may help reduce relapse rates, length of hospital stay, and surgical intervention rates by providing appropriate treatment. Methodology: We examined 220 adult patients diagnosed with Brucellosis in our tertiary care hospital in the Black Sea Region between January 01, 2010, and January 01, 2022. Patients with and without bacteremia and complications were compared regarding demographic characteristics, clinical features, and laboratory parameters. Results: The mean age was 46.4 ± 15.8 years (18-96 years), and 61% were male. Low back pain and absence of muscle pain were independent risk factors for predicting bacteremia (p = 0.049, p = 0.043, respectively). Weakness /fatigue, weight loss, and 1/320 Standard Tube Agglutination Test (STAT) or Brucella Coombs Gel Test (BCGT) titers were independent risk factors that reduced the risk of complications; in contrast, low back pain and splenomegaly were independent risk factors for development of complications. (p = 0.025, p = 0.007, p = 0.008, p = 0.003, p = 0.021 respectively). Thrombocytopenia was related to complications. When the platelet cut-off value was taken as 160,000/µL in predicting complications, the sensitivity was 31.30%, and the specificity was 97.73% (p = 0.011). Conclusions: The risk of clinical progression and complications could be predicted with symptoms and signs such as myalgia, low back pain, weakness/fatigue, weight loss, splenomegaly, and easily accessible laboratory parameters such as serum STAT/BCGT titer and platelet level.